Do you want to offer a transformative approach to osteoarthritis to your canine patients? Read on to find out how you can make stem cell therapy possible in practice and register for our free on-demand webinar ‘Stem Cell Therapy in OA: Making it possible in Practice’ by Dr Russell Chandler. Canine osteoarthritis (OA) affects 20-40% of dogs (1,2), increasing to 80% of geriatric dogs (2). OA is incurable and progressive (3,4), with a high welfare impact, therefore it can be a significant contributor to euthanasia decisions (4,5).

The key goals of osteoarthritis management (6) include:

– Pain management

– Reduce inflammation

– Improve quality of life

– Limit disease progression

Conventional treatments, such as NSAIDS, or the newer monoclonal antibodies, can be very effective for pain management, and improve patient quality of life, but are unable to limit disease progression.

Stem cell possess potential tissue regenerative properties (7,8) and therefore present an exciting new approach to OA management with considerable clinical potential.

How do stem cells work?

Following intra-articular administration, stem cells become activated by inflammatory cytokines in the arthritic joint and through a range of mechanisms (9), exert the following effects:

– Immunomodulation – transforming the joint environment from inflammatory to non-inflammatory

– Anti-inflammatory – targeting pain and inflammation

– Potential tissue regenerative properties – potential to slow disease progression (3,8,10)

When to use stem cells and what to expect?

Stem cells should be considered for every canine patient with OA as part of a multi-modal approach, including; analgesics, adiposity management, diet, exercise and surgical intervention (where appropriate).

Unleash the transformative power of stem cells with DogStem®

· The first and only licensed stem cell therapy for mild-severe canine OA of the hip and elbow (7)

· Ready-to-use intra-articular injection

· From 3 months to more than 12 months’ efficacy following a single dose (10)

· Clinically proven to reduce pain and lameness and improve mobility and quality of life (10)

· Targeted local action – no systemic contraindications

Free Webinar

To find out more about how you can bring stem cell therapy to your patients, register for free on-demand access to our webinar which will be available to watch on The Webinar Vet from Monday the 30th of January: ‘Stem Cell Therapy in OA: Making it possible in Practice’, where Dr Russell Chandler discusses:

– How stem cell therapy works and its importance in the management of canine osteoarthritis

– What the sources of stem cells are and how do these differ

– Which patients are good candidates for stem cell therapy

– How does stem cell therapy fit into case management (when to use it)

– What to expect from stem cell therapy and the long-term management of OA.

This webinar is sponsored by DogStem®, the first and only licensed stem cell therapy for mild to severe canine osteoarthritis in the UK/EU.

Speak to your TVM territory manager or visit us at www.dogstem.co.uk to find out more about how you can bring DogStem® to your patients.

References:

1. Enomoto, M., et al. (2022). Prevalence of radiographic osteoarthritis and associated clinical signs in young dogs. Poster presented at NC State College of Veterinary Medicine Research Forum 1st April 2022. [Available online at: https://www.ncsu-cprec.com/research-abstracts Accessed 07.09.2022]​

2. Johnston, S.A. (1997). Osteoarthritis. Joint anatomy, physiology, and pathobiology. ​The Veterinary Clinics of North America: Small Animal Practice. 27(4), 699–723. ​

3. Brondeel, C., et al. (2021). Review: Mesenchymal stem cell therapy in canine osteoarthritis research: “Experientia Docet” (Experience Will Teach Us). Frontiers in Veterinary Science 8, 668881. ​

4. Spitznagel, M.B., et al. (2022). Relationships among owner consideration of euthanasia, caregiver burden, and treatment satisfaction in canine osteoarthritis. The Veterinary Journal, p.105868.​

5. O’Neill, D. G., et al. (2020). Epidemiology and clinical management of elbow joint disease in dogs under primary veterinary care in the UK. Canine Medicine and Genetics, 7(1), 1-15.​

6. Millis, D. (2021). Multimodal pain management for canine osteoarthritis. Today’s Veterinary Practice. https://todaysveterinarypractice.com/pain_management/multimodal-pain-management-for-canine-osteoarthritis/ [Accessed 06/10/22]​

7. DogStem® suspension for injection for dogs SPC

8. Kriston-Pál, É., et al. (2017). Characterization and therapeutic application of canine adipose mesenchymal stem cells to treat elbow osteoarthritis. Canadian Journal of Veterinary Research – Revue Canadienne de Recherche Veterinaire. 81(1), 73-78.

9. Spees, J. L., Lee, R. H., & Gregory, C. A. (2016). Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Research & Therapy, 7(1), 1-13.7.

10. Punzón, E., et al. (2022). Equine umbilical cord mesenchymal stem cells demonstrate safety and efficacy in the treatment of canine osteoarthritis: a randomized placebo-controlled trial. Journal of the American Veterinary Medical Association. ​

DogStem is licensed for the improvement in function and reduction of pain and lameness associated with mild to severe osteoarthritis in hip and elbow joints. DogStem suspension for injection for dogs contains 7.5 million equine umbilical cord mesenchymal stem cells. Legal category POM-V.
For more information, please view the full SPC or contact TVM-UK Animal Health Ltd, Kirtlington Business Centre, Slade Farm, Kirtlington, Oxfordshire, OX5 3JA, UK Tel: 0800 0385868 | Email: help@tvm-uk.com | www.tvm-uk.com Use medicines responsibly. www.noah.co.uk/responsible Advice should be sought from the medicine prescriber.